« Return to News | Clinical Intelligence

FDA grants Soligenix Fast Track designation for SGX203 for Crohn's disease

Friday, November 9, 2012 12:44 PM

Soligenix, a development stage biopharmaceutical company based in Princeton, N.J., announced that its drug SGX203, for the treatment of mild-to-moderate pediatric Crohn's disease, has received Fast Track designation from the FDA.

SGX203 contains BDP, a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. SGX203 is a two tablet delivery system (immediate and delayed release) of BDP specifically designed for oral use that allows for delivery of BDP throughout the small bowel and the colon. The FDA previously awarded SGX203 Orphan Drug designation for the treatment of pediatric Crohn's disease.

"There are no FDA approved corticosteroid therapies for the induction treatment of Crohn's disease in the pediatric population," said Christopher J. Schaber, PhD, president and CEO,  Soligenix. "The FDA's action in granting Fast Track designation is an indication of SGX203's potential to address this debilitating, unmet medical need.  We look forward to working closely with the FDA to potentially expedite the development and NDA review process."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.